VERX - Vertex, Inc.
Only 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical Only 12% of organizations globally have fully integrated tax technology, even as real-time compliance becomes business critical
Vertex NASDAQ: VERX reported first-quarter 2026 results above its guidance range and raised its full-year profitability outlook as management outlined a cost-reduction program intended to fund investments in e-invoicing, compliance and artificial intelligence.
Vertex remains a "Buy" as its tax compliance software business shows resilience amid broad SaaS sector weakness. Despite a ~20% YTD and 60% 1-year decline, VERX delivered a strong Q1 beat-and-raise, with accelerating growth and expanding margins. Fears of AI disruption are overblown for VERX, given the complexity and criticality of tax compliance, reinforcing its competitive moat.
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Vertex (VERX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Vertex (VERX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.15 per share a year ago.
KING OF PRUSSIA, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading provider of enterprise compliance technology for global commerce, today announced financial results for its first quarter ended March 31, 2026.
Vertex Pharmaceuticals Incorporated delivered strong Q1 2026 earnings, with $2.99bn revenue and $4.02 EPS, but revenue growth is slowing as CF market saturates. VRTX's cystic fibrosis franchise remains dominant and highly profitable, but diversification efforts—Casgevy, Journavx, and povetacicept—face slow uptake or intense competition. Forward P/E of ~26.5x and P/S of ~8.3x are above Big Pharma averages, reflecting market concerns about future growth for VRTX beyond CF.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia. “For the first time in Germany, a long-t.
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday.
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 financial guidance. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “CASGEVY and J.
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
On April 24, 2026, Vertex Inc (VERX) shares rose 7.2% today, currently trading at $12.52. The stock has fluctuated within a 52-week range of $10.59 to $42.44, r
Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal, and gene therapies. VRTX's CF franchise continues to grow via ALYFTREK's launch, geographic expansion, and penetration into younger and rare mutation populations, supporting robust revenue. New products JOURNAVX and CASGEVY are gaining traction, and the renal pipeline—especially povetacicept—could become a second franchise with multi-billion-dollar potential.
Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, Vertex Pharmaceuticals' core franchise looks safe for the foreseeable future.
KING OF PRUSSIA, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. A conference call to discuss the results will be held at 8:30 a.m. Eastern Time that same day.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast can be.
Aberdeen Group plc lessened its stake in Vertex, Inc. (NASDAQ: VERX) by 15.5% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,221,776 shares of the company's stock after selling 224,058 shares during the quarter. Aberdeen Group plc owned approximately 0.77% of Vertex worth $24,399,000
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has been given an average rating of "Hold" by the fifteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and seven have given a buy recommendation to the company. The